Back to Search Start Over

Use of Low-Molecular-Weight Heparin and Peak anti-Xa Monitoring In Severe SARS-CoV-2 Disease: A Brief Report.

Authors :
Toor R
Zamora FJ
Fatteh N
Drexler N
Lozada J
Source :
Hospital pharmacy [Hosp Pharm] 2021 Dec; Vol. 56 (6), pp. 640-645. Date of Electronic Publication: 2020 Sep 08.
Publication Year :
2021

Abstract

In 2019, a novel coronavirus was identified in Wuhan, China. This strain was classified as a pandemic in early 2020 by the World Health Organization (WHO), rapidly reaching millions of cases worldwide and overwhelming intensive care units. One distinct feature identified in severe SARS-CoV-2 is abnormal and complex coagulation and hematologic abnormalities, including significantly elevated D-dimer and fibrin/fibrinogen values possibly increasing morbidity and mortality in this patient population. Aggressive anticoagulation therapy with appropriate peak anti-Xa level monitoring has produce satisfactory results at our institution. Our intent is to present a case series of our strategy to highlight the benefits of this approach.<br />Competing Interests: Declaration of Conflicting Interests: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.<br /> (© The Author(s) 2020.)

Details

Language :
English
ISSN :
0018-5787
Volume :
56
Issue :
6
Database :
MEDLINE
Journal :
Hospital pharmacy
Publication Type :
Academic Journal
Accession number :
34732915
Full Text :
https://doi.org/10.1177/0018578720954154